Investor Presentation

90 Investor presentation First six months of 2022 Ziltivekimab phase 2b RESCUE trial was successfully completed In the RESCUE trial, zilti QM showed reduction in hsCRP at all dose placebo I ziltivekimab 15 mg levels Iziltivekimab 7.5 mg I ziltivikemab 30 mg 2 % change¹ 0% 12 weeks of treatment End of treatment -3% -5% -20% -40% -60% -80% -77% * -88% -92% -100% * -79% * -91% -93% Zilti QM showed reductions in inflammation biomarkers³ Zilti QM appeared to have a safe and well-tolerated profile Novo NordiskⓇ Addressing the residual risk of CVD for more than 5 million patients with ASCVD, CKD, and inflammation4 The phase 3 cardiovascular outcomes trial was initiated as of Q3 2021 1 Primary endpoint was the median percent change in hsCRP, * Indicates statistical significance, p < .0001 2 End of treatment is defined as the average of values at week 23 and week 24 3 Inflammation biomarkers include: Fibrinogen, serum amyloid A, haptoglobin and NTproBNP 4 Inflammation is defined as c-reactive protein levels greater than 2 Zilti: Ziltivekimab; QM: Once-montly; hsCRP: High-sensitivity C-reactive protein; CVD: Cardiovascular disease; ASCVD: Atherosclerotic cardiovascular disease; CKD: Chronic kidney disease

View entire presentation